Page 95 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes

donepezil 5 mg placebo donepezil 10 mg 71 72 72 55 57 61 99% 99% 100% 1% 1% <1% 20 20 20 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Secondary Outcome Measures: CDR-SB; patient rated quality of life (scale not specified but reported in Rogers et al., 1998); modified IDDD Timing of assessments: Baseline and weeks 6, 12, 18, 24 and 30 (endpoint = 24 weeks; placebo washout phase = 30 weeks; outcome measures reported for 24 weeks) Health Outcome Measures: No significant differences in quality of life scores at any time during t

• • • • •

Final Report Update 1 Authors: Burns et al. Year: 1999 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Other • Other germane population qualities: Baseline mean MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs